Develops therapies for cancer and neurological diseases, focusing on targeting cancer stem cells and central nervous system disorders.
Kazia Therapeutics Limited is a biotechnology company with a focused commitment to advancing oncology treatments. The company specializes in the development of innovative anti-cancer drugs designed to address significant unmet medical needs. Central to its pipeline is Paxalisib, a brain-penetrant inhibitor targeting the PI3K/Akt/mTor pathway, specifically tailored as a potential therapy for glioblastoma, a particularly challenging form of brain cancer.
In addition to Paxalisib, Kazia Therapeutics is actively developing EVT801, an investigational new drug intended for the treatment of various cancers. This diverse portfolio underscores the company's dedication to expanding treatment options and improving outcomes for cancer patients worldwide.
Originally incorporated in 1994 as Novogen Limited and subsequently rebranded in November 2017, Kazia Therapeutics Limited is headquartered in Sydney, Australia. With a rich history in oncology research and development, the company continues to leverage its expertise to drive forward innovative therapies that hold promise in the fight against cancer.